Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma

Author:

Maekawa Keiko12ORCID,Ri Masaki34ORCID,Nakajima Miki56,Sekine Akihiro7,Ueda Ryuzo8,Tohkin Masahiro9,Miyata Naoki10,Saito Yoshiro2,Iida Shinsuke3ORCID

Affiliation:

1. Department of Analytical Chemistry Faculty of Pharmaceutical Sciences Doshisha Women's College of Liberal Arts Kyoto Japan

2. Division of Medical Safety Science National Institute of Health Sciences Kawasaki Japan

3. Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan

4. Division of Blood Transfusion Nagoya City University Graduate School of Medical Sciences Nagoya Japan

5. Drug Metabolism and Toxicology Faculty of Pharmaceutical Sciences Kanazawa University Kanazawa Japan

6. WPI Nano Life Science Institute Kanazawa University Kanazawa Japan

7. Center for Preventive Medical Science Chiba University Chiba Japan

8. Department of Tumor Immunology Aichi Medical University School of Medicine Nagakute Japan

9. Department of Regulatory Science Graduate School of Pharmaceutical Sciences Nagoya City University Nagoya Japan

10. Institute of Drug Discovery Science Nagoya City University Nagoya Japan

Funder

Ministry of Health, Labour and Welfare

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3